Valoa’s noninvasive blood glucose monitoring technology is protected by US and international patents and patent applications.
Individual calibration with durability has been demonstrated. Ten test subjects were measured for two days each, a PLS model for each subject was established on Day 1 data and then applied to Day 2 data. The 579 data pairs of Day 2 yield a correlation between the blood-test measured blood glucose and the device result of 0.593, a Mean Absolute Relative Deviation (MARD) of 19.7%, with an extremely statistically significant p-value of 8·10-44. Original article here.
These results should actually have been better; read the report here.
The need for individual calibration would make for an unsatisfactory product. Therefore, Valoa is developing a universal calibration that will allow anybody to use the device straight out of the box. Some restrictions will apply, such as a minimum and a maximum earlobe thickness. It is estimated that about 90% of the general population will be able to use the device.